Hangzhou Saihe Biotechnology Co., Ltd. has recently announced the successful closure of its Angel+ round of financing, raising tens of millions. This round was spearheaded by its existing shareholder, Fir Capital, with additional co-investment from Longtai Investment. The influx of capital will be strategically directed towards accelerating the clinical trials of its core product pipelines, fostering the development of foundational innovative technologies within the nuclear medicine realm, and attracting top-tier talent.

Established in October 2024, Saihe Biotech boasts a core team comprised of seasoned experts hailing from renowned institutions. The company has honed its focus on the cutting-edge field of alpha radionuclides, armed with a globally pioneering radionuclide conjugation platform technology. Fir Capital has expressed confidence in Saihe Biotech's technological vision and the prowess of its team. Meanwhile, Longtai Investment remains bullish on the nuclear medicine sector, particularly impressed by Saihe Biotech's novel approach to radionuclide delivery.

Nuclear medicine, a vanguard in the global precision medical industry's ongoing revolution, has increasingly captured the spotlight. Against this backdrop, the 3rd Global Nuclear Medicine Development Summit is slated to take place in Shanghai from March 19 to 20, 2026, promising to be a pivotal event for industry stakeholders.